RANI vs. ATAI, KOD, RZLT, NMRA, ATYR, EYEN, ENGN, CMPS, VYGR, and BTMD
Should you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Atai Life Sciences (ATAI), Kodiak Sciences (KOD), Rezolute (RZLT), Neumora Therapeutics (NMRA), Atyr PHARMA (ATYR), Eyenovia (EYEN), enGene (ENGN), COMPASS Pathways (CMPS), Voyager Therapeutics (VYGR), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry.
Rani Therapeutics vs.
Rani Therapeutics (NASDAQ:RANI) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.
In the previous week, Rani Therapeutics had 4 more articles in the media than Atai Life Sciences. MarketBeat recorded 9 mentions for Rani Therapeutics and 5 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 0.84 beat Rani Therapeutics' score of 0.50 indicating that Atai Life Sciences is being referred to more favorably in the news media.
Atai Life Sciences received 300 more outperform votes than Rani Therapeutics when rated by MarketBeat users. However, 82.05% of users gave Rani Therapeutics an outperform vote while only 66.40% of users gave Atai Life Sciences an outperform vote.
Rani Therapeutics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.
Rani Therapeutics has higher earnings, but lower revenue than Atai Life Sciences. Atai Life Sciences is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are held by institutional investors. 53.3% of Rani Therapeutics shares are held by insiders. Comparatively, 31.2% of Atai Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Atai Life Sciences' return on equity of -65.75% beat Rani Therapeutics' return on equity.
Rani Therapeutics presently has a consensus target price of $12.33, indicating a potential upside of 774.70%. Atai Life Sciences has a consensus target price of $9.00, indicating a potential upside of 303.59%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Rani Therapeutics is more favorable than Atai Life Sciences.
Summary
Rani Therapeutics beats Atai Life Sciences on 10 of the 17 factors compared between the two stocks.
Get Rani Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Rani Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:RANI) was last updated on 2/12/2025 by MarketBeat.com Staff